Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLL2-GiVe: Ibrutinib, Venetoclax, and Obinutuzumab in Untreated CLL with TP53 Alterations
NCT02758665Phase 2Completed
- Sponsor
- Ulm University
- Start
- Sep 2016
- Primary completion
- Jan 2022
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib, venetoclax, obinutuzumab in chronic lymphocytic leukemia (CLL), sponsored by Ulm University. Started Sep 2016; status: completed.
02
Drugs
ibrutinibvenetoclaxobinutuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02758665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02758665.